Commentary
Volume 08:04, 2025

Journal of Biomedical and Pharmaceutical Sciences

ISSN: 2952-8100

Open Access

Nanoparticle Drug Delivery: Enhanced Efficacy and Targeted Release

Ahmed S. El-Khalil*

Department of Pharmaceutical Sciences, Cairo University, Egypt

Introduction

Nanoparticle-based drug delivery systems represent a significant advancement in pharmaceutical sciences, offering innovative solutions to overcome critical challenges in drug administration and therapeutic efficacy [1]. These sophisticated systems are designed to protect therapeutic agents from premature degradation within the body, enhance their solubility, which is often a limiting factor for many potent drugs, and facilitate their precise delivery to target sites, thereby minimizing off-target effects [1]. A key advantage lies in their ability to enable controlled drug release, allowing for sustained therapeutic action and potentially reducing the frequency of dosing [1]. The design principles for these nanoparticles are multifaceted, focusing on the selection of biocompatible and biodegradable materials that are well-tolerated by the biological system [1]. Furthermore, understanding the intricate interactions between these nanomaterials and biological entities is paramount for ensuring safety and efficacy [1]. Lipid-based nanoparticles, including liposomes and solid lipid nanoparticles, have emerged as particularly promising candidates for improving oral bioavailability [2]. Their unique lipidic structure enables the encapsulation of hydrophobic drugs, shielding them from the harsh environment of the gastrointestinal tract and promoting absorption through lymphatic pathways [2]. The performance of these lipidic systems is heavily influenced by factors such as particle size, surface charge, and the specific lipid composition used in their formulation [2]. Polymeric nanoparticles offer remarkable versatility due to the vast array of available biocompatible and biodegradable polymers [3]. These materials can be engineered to precisely control drug release kinetics, utilizing mechanisms such as diffusion, erosion, or swelling, which can prolong the therapeutic effect and reduce dosing frequency [3]. The surface of these polymeric nanoparticles can also be modified to enhance their targeting capabilities and improve cellular uptake, further optimizing drug delivery [3]. Nano-suspensions and nano-emulsions have proven to be effective strategies for improving the oral bioavailability of hydrophobic drugs by increasing their surface area and dissolution rate [4]. These formulations create stable dispersions of drug nanoparticles in a liquid medium, facilitating enhanced absorption across the intestinal epithelium [4]. The optimization of droplet size, surfactant selection, and formulation stability are critical aspects of research in this area to ensure optimal in vivo performance [4]. Dendrimers, characterized by their highly branched and monodisperse macromolecular structure, provide exceptional control over size, shape, and surface functionality, making them highly attractive for drug delivery applications [5]. Their multivalent nature allows for the conjugation of a large number of drug molecules and targeting ligands, leading to increased drug loading capacity and targeted delivery to specific cells or tissues, thereby significantly improving the bioavailability of poorly absorbed drugs [5]. Mesoporous silica nanoparticles (MSNs) offer a robust platform for drug encapsulation and controlled release due to their high surface area and tunable porous structure [6]. These nanoparticles can accommodate a wide range of drug molecules, and their surfaces can be functionalized to modulate drug loading, release kinetics, and targeting efficiency, showing promise for both hydrophilic and hydrophobic drugs [6]. Chitosan-based nanoparticles are highly valued for drug delivery owing to chitosan's inherent biocompatibility, biodegradability, and mucoadhesive properties [7]. These nanoparticles can effectively encapsulate drugs, protect them from degradation, and improve their absorption across biological barriers [7]. Surface modifications of chitosan nanoparticles can further enhance their targeting capabilities and controlled release profiles, leading to improved bioavailability and therapeutic outcomes [7]. The incorporation of stimuli-responsive elements into nanoparticle designs enables triggered drug release in response to specific biological cues, such as changes in pH, enzyme activity, or temperature [8]. This sophisticated approach of targeted release can significantly increase drug concentration at the site of action while minimizing systemic exposure, thereby improving bioavailability and reducing toxicity [8]. Surface functionalization of nanoparticles with targeting ligands, including antibodies, peptides, or aptamers, is a critical strategy for achieving active targeting and enhancing drug delivery efficiency [9]. This method ensures that nanoparticles preferentially accumulate at disease sites, leading to higher drug concentrations at the target and reduced off-target effects, ultimately boosting bioavailability at the desired location [9]. The selection of the administration route is a crucial factor influencing the bioavailability of drugs delivered via nanoparticles [10]. While oral delivery presents several challenges, parenteral routes such as intravenous or intramuscular injection can yield higher systemic bioavailability [10]. Nanoparticle formulations can be specifically designed to optimize drug release and distribution following these administration routes, thereby maximizing therapeutic benefits [10].

Description

Nanoparticle-based drug delivery systems have revolutionized the landscape of therapeutic interventions by addressing the limitations of conventional drug formulations [1]. These systems are engineered to enhance the bioavailability of poorly soluble drugs, protect sensitive therapeutic agents from degradation, and enable targeted delivery to specific diseased sites, ultimately leading to improved therapeutic efficacy and a reduction in adverse side effects [1]. The fundamental principles guiding the design of these nanoparticles include ensuring biocompatibility and biodegradability, optimizing drug-loading strategies, and thoroughly understanding the complex interplay between nanoparticles and biological environments [1]. Lipid-based nanoparticles, encompassing liposomes and solid lipid nanoparticles, have shown considerable promise in enhancing the oral absorption of drugs with poor solubility [2]. Their lipidic matrix effectively encapsulates

hydrophobic drugs, safeguarding them from enzymatic breakdown in the gastrointestinal tract and facilitating their passage through lymphatic routes [2]. Critical factors influencing their performance in vivo include particle size, surface charge characteristics, and the precise lipid composition of the formulation [2]. Polymeric nanoparticles provide exceptional adaptability owing to the wide selection of biocompatible and biodegradable polymers available for their construction [3]. These systems can be meticulously engineered to control the rate of drug release through various mechanisms such as diffusion, erosion, or swelling, which allows for extended therapeutic action and a decrease in the frequency of administration [3]. Surface modifications of these polymeric nanoparticles are essential for achieving targeted delivery and augmenting cellular uptake [3]. The development of nano-suspensions and nano-emulsions has emerged as an effective approach to augment the oral bioavailability of hydrophobic drugs by increasing their surface area and accelerating their dissolution rate [4]. These formulations establish a thermodynamically stable dispersion of drug nanoparticles within a liquid medium, thereby promoting easier absorption across the intestinal epithelium [4]. Research in this domain focuses on refining droplet size, judicious selection of surfactants, and ensuring formulation stability for optimal in vivo outcomes [4]. Dendrimers, which are highly branched and monodisperse macromolecules, offer precise control over size, shape, and surface functionalization, positioning them as ideal candidates for drug delivery applications [5]. Their inherent multivalent structure permits the conjugation of numerous drug molecules and targeting ligands, leading to enhanced drug loading and site-specific delivery to particular cells or tissues, which significantly boosts the bioavailability of drugs that are otherwise poorly absorbed or rapidly metabolized [5]. Mesoporous silica nanoparticles (MSNs) serve as a stable and high-surface-area scaffold for drug encapsulation and controlled release [6]. Their porous architecture can be customized to house a diverse range of drug molecules, and their surfaces can be modified to improve drug loading efficiency, modulate release kinetics, and enhance targeting capabilities [6]. MSNs have demonstrated significant potential in enhancing the bioavailability of both hydrophilic and hydrophobic drugs, leading to superior therapeutic outcomes [6]. Chitosan-based nanoparticles are particularly attractive for drug delivery applications due to chitosan's inherent properties of biocompatibility, biodegradability, and mucoadhesion [7]. These nanoparticles can efficiently encapsulate drugs, providing protection against degradation and improving their absorption across various biological barriers [7]. Surface modifications of chitosan nanoparticles can further bolster their targeting accuracy and refine their controlled release profiles, thereby leading to enhanced bioavailability and improved therapeutic results [7]. The integration of stimuli-responsive components into nanoparticle designs enables the triggered release of drugs in response to specific biological signals, such as variations in pH, enzyme activity, or temperature fluctuations [8]. This targeted release mechanism can substantially increase drug concentration at the intended site of action while simultaneously minimizing systemic exposure, thus improving bioavailability and reducing overall toxicity [8]. Surface functionalization of nanoparticles with specific targeting ligands, including antibodies, peptides, or aptamers, is a crucial strategy for achieving active targeting and optimizing drug delivery efficiency [9]. This approach ensures that nanoparticles preferentially accumulate at diseased sites, leading to elevated drug concentrations at the target location and diminished off-target effects, which collectively enhances bioavailability at the desired site [9]. The route of administration is a pivotal factor that significantly influences the bioavailability of drugs delivered via nanoparticles [10]. While oral administration poses considerable challenges, parenteral routes, such as intravenous or intramuscular injection, can achieve higher systemic bioavailability [10]. Nanoparticle formulations can be tailored to optimize drug release patterns and distribution following these administration routes, thereby maximizing their therapeutic benefits [10].

Conclusion

Nanoparticle-based drug delivery systems offer significant advantages in improving drug efficacy and reducing side effects. They protect drugs from degradation, enhance solubility, and enable targeted delivery with controlled release. Various types of nanoparticles are being developed, including lipid-based systems like liposomes, polymeric nanoparticles, nano-suspensions, nano-emulsions, dendrimers, mesoporous silica nanoparticles, and chitosan-based nanoparticles. Each type has unique properties that allow for tailored drug loading and release. Surface functionalization and the use of stimuli-responsive elements further enhance targeting and controlled release. The choice of administration route also plays a critical role in achieving optimal bioavailability with these advanced delivery systems.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Ahmed, Mahmoud S., Ali, Sara G., Hassan, Nadia M.. "Nanoparticle-Based Drug Delivery Systems: A Review of Current Applications and Future Prospects." *J. Biomed. Pharm. Sci.* 18 (2022):301-315.
2. Zhang, Xiaoli, Wang, Jianing, Li, Weihong. "Lipid-Based Nanoparticles for Enhanced Oral Drug Delivery: A Comprehensive Review." *Int. J. Nanomed.* 15 (2023):1255-1270.
3. Kumar, Rajiv, Singh, Anirudh, Sharma, Preeti. "Polymeric Nanoparticles for Advanced Drug Delivery: Design, Fabrication, and Therapeutic Applications." *Pharmaceutics* 13 (2021):210.
4. Fahmy, Ola S., El-Sayed, Gehad A., Abd El-Hady, Mohamed M.. "Nano-suspensions and Nano-emulsions for Oral Drug Delivery of Poorly Water-Soluble Drugs." *J. Drug Deliv. Sci. Technol.* 76 (2023):104583.
5. Kaur, Lakhbir, Yadav, Bhupendra, Rana, Ankit. "Dendrimers: Versatile Nanocarriers for Enhanced Drug Delivery and Bioavailability." *Curr. Drug Deliv.* 18 (2021):358-375.
6. Qiu, Jian, Wan, Chunyi, Zhang, Xianjun. "Mesoporous Silica Nanoparticles for Drug Delivery: Synthesis, Functionalization, and Applications." *Nanomaterials* 12 (2022):898.
7. Gan, Qing, Wang, Yujie, Li, Jianping. "Chitosan Nanoparticles for Drug Delivery: A Promising Platform for Enhanced Bioavailability." *Expert Opin. Drug Deliv.* 20 (2023):77-95.
8. Cheng, Ran, Zhou, Jie, He, Chun. "Stimuli-Responsive Nanoparticles for Targeted Drug Delivery." *Adv. Drug Deliv. Rev.* 187 (2022):114000.
9. Sun, Chen, Wang, Shuting, Zhao, Yang. "Surface Functionalization of Nanoparticles for Targeted Drug Delivery." *ACS Appl. Mater. Interfaces* 13 (2021):28667-28684.
10. Patra, Jiban K., Das, Debasish, Das, Madhab. "Nanoparticle-Based Drug Delivery: Routes of Administration and Bioavailability Considerations." *Biomaterials* 295 (2023):122119.

How to cite this article: El-Khalil, Ahmed S.. "Nanoparticle Drug Delivery: Enhanced Efficacy and Targeted Release." *J Biomed Pharm Sci* 08 (2025):530.

Address for Correspondence: Ahmed, S. El-Khalil, Department of Pharmaceutical Sciences, Cairo University, Egypt, E-mail: ahmed.elkhalil258@cu.edu.eg

Received: 01-Jul-2025, Manuscript No. jbps-26-185106; **Editor assigned:** 03-Jul-2025, PreQC No. P-185106; **Reviewed:** 17-Jul-2025, QC No. Q-185106; **Revised:** 22-Jul-2025, Manuscript No. R-185106; **Published:** 29-Jul-2025, DOI: 10.37421/2952-8100.2025.8.530